The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...